Close menu

Immunotherapy: Tollys presents new data at OTS 2022, demonstrating anti-tumor activity of TL-532


Results highlight specificity of TLR3-agonist TL-532, that induces lifelong anti-tumor auto-vaccination and reverses resistance to immune checkpoint inhibitors.
Results to be presented at 18th Congress of Oligonucleotide Therapeutics Society (OTS) in Phoenix on October 2-5, 2022.


Read the press release